Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the monoclonal antibody.
Indication and Usage:
Kadcyla is used to treat tumors that produce more than the normal amount of a certain substance called HER2 protein. ado-trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
Side Effects:
Common side effects ofKadcyla (ado trastuzumab emtansine) includes:
Diarrhea, redness/irritation at the injection site, dizziness, muscle/joint/back pain, stomach/abdominal pain, constipation, trouble sleeping, nausea, vomiting, mouthsores, dry mouth, changes in taste, and loss of appetite may occur
Dosage form & Strength:
Kadcyla (ado trastuzumab emtansine) for injection 100mg/vial WholeSaler, distributor, supplier
Kadcyla (ado trastuzumab emtansine) for injection 160mg/vial WholeSaler, distributor, supplier
Rasso Swiss Pharma is a WholeSaler, Distributor for Kadcyla (Ado-trastuzumab emtansine).
